Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial plannednews2024-12-20T11:13:59+00:00December 20th, 2024|Endpoints News|
Regeneron forges ahead in factor XI despite field’s mixed resultsnews2024-12-19T18:27:20+00:00December 19th, 2024|Endpoints News|
Sorriso claims a Phase 1b success for oral antibody in ulcerative colitisnews2024-12-19T15:00:07+00:00December 19th, 2024|Endpoints News|
Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain studynews2024-12-19T12:21:09+00:00December 19th, 2024|Endpoints News|
Roche’s Parkinson’s drug flunks second mid-stage trialnews2024-12-19T11:52:50+00:00December 19th, 2024|Endpoints News|
Biosecure Act influence still felt even as China bill stallsnews2024-12-18T19:41:08+00:00December 18th, 2024|Endpoints News|
Exclusive: Insitro finds new ALS drug target in Bristol Myers dealnews2024-12-18T12:00:57+00:00December 18th, 2024|Endpoints News|
Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trialnews2024-12-18T12:00:43+00:00December 18th, 2024|Endpoints News|
Regeneron looks to expand label of Eylea HD early next yearnews2024-12-17T18:07:22+00:00December 17th, 2024|Endpoints News|
UCB, Novartis say a Phase 2a Parkinson’s study failednews2024-12-17T14:59:04+00:00December 17th, 2024|Endpoints News|
